‘Best Biotech’ Prix Galien USA Awarded to GBT’s Oxbryta

‘Best Biotech’ Prix Galien USA Awarded to GBT’s Oxbryta

311535

‘Best Biotech’ Prix Galien USA Awarded to GBT’s Oxbryta

Oxbryta (voxelotor), Global Blood Therapeutics’ first-in-class oral therapy for sickle cell disease (SCD), has won the 2021 Prix Galien USA Award for best biotechnology product. The award is among the health industry’s most prestigious honors, and recognizes an outstanding product that has improved patient well-being and impacted human health. Proven to stop the sickling and destruction of red blood cells in SCD, Oxbryta was selected from a pool of 19 candidates by a panel of…

You must be logged in to read/download the full post.